A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

NCT00692458 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Withdrawn for administrative reasons

Conditions

Breast Cancer

Interventions

DRUG: Comparator: odanacatib
DRUG: Comparator: placebo

Sponsor

Merck Sharp & Dohme LLC